CAVACURMIN (Curcuma longa)

CAVACURMIN is a patented curcumin extract derived from Curcuma longa, engineered using cyclodextrin complexation technology to dramatically improve the notoriously poor oral bioavailability of curcumin. Its primary bioactive compound, curcumin (diferuloylmethane), modulates NF-κB signaling, COX-2 enzyme activity, and pro-inflammatory cytokine cascades upon absorption.

Origin & History

CAVACURMIN is a branded curcumin formulation derived from the rhizomes of Curcuma longa L. (turmeric), a perennial herbaceous plant native to South Asia. It is extracted using various methods including conventional solvent extraction (ethanol at 30°C), microwave-assisted extraction (MAE), ultrasound-assisted extraction (UAE), and accelerated solvent extraction (ASE), with yields varying from 3.8-4.98% depending on the method.

Historical & Cultural Context

Curcuma longa (turmeric) rhizomes have historical use in traditional medicine systems. However, the research dossier provides no specific details about duration of use, traditional medicine systems like Ayurveda, or traditional therapeutic applications beyond noting the plant as the source material.

Health Benefits

• No clinical health benefits documented - research focuses solely on extraction methods
• No evidence quality available - no human trials conducted on CAVACURMIN
• No therapeutic outcomes reported - available data limited to extraction yields
• No meta-analyses or RCTs found - research dossier contains only extraction studies
• No specific health claims can be made based on provided research

How It Works

Curcumin, the primary polyphenol in CAVACURMIN, inhibits IκB kinase (IKK), thereby suppressing NF-κB nuclear translocation and downstream transcription of inflammatory mediators including TNF-α, IL-1β, and IL-6. It also directly inhibits cyclooxygenase-2 (COX-2) and lipoxygenase (LOX) enzymes, reducing prostaglandin E2 synthesis. The cyclodextrin complexation used in CAVACURMIN increases aqueous solubility of curcumin, theoretically improving intestinal absorption compared to unformulated curcumin powder.

Scientific Research

No human clinical trials, RCTs, or meta-analyses were found for CAVACURMIN in the research dossier. All available studies focus exclusively on extraction methods and yields without any therapeutic efficacy testing or clinical outcomes. No PubMed PMIDs are provided for any clinical studies.

Clinical Summary

As of available research dossiers, no published human clinical trials have been conducted specifically on the CAVACURMIN trademarked formulation to evaluate therapeutic outcomes. Existing research on this ingredient is confined to in vitro extraction yield studies and solubility characterization data, meaning no randomized controlled trials (RCTs) or meta-analyses exist for this specific product. While the broader curcumin literature includes hundreds of human trials examining inflammation, joint health, and metabolic parameters, these findings cannot be directly extrapolated to CAVACURMIN without formulation-specific bioavailability and efficacy data. Evidence strength for CAVACURMIN-specific health claims must currently be rated as insufficient.

Nutritional Profile

CAVACURMIN is a specialized curcumin extract derived from Curcuma longa (turmeric) root, formulated using cavitation-based extraction technology to enhance bioavailability. Primary bioactive compound: curcuminoids complex comprising curcumin (typically 75-85% of curcuminoid fraction), demethoxycurcumin (15-20%), and bisdemethoxycurcumin (3-5%), with total curcuminoid concentration standardized typically to 95% curcuminoids by weight in the extract form. The cavitation extraction process is specifically designed to increase water dispersibility and oral bioavailability of curcumin, which in its native form has poor aqueous solubility (<1 mg/L) and limited intestinal absorption. Essential oils from Curcuma longa present in base material include ar-turmerone, turmerone, and zingiberene at trace concentrations. Naturally occurring micronutrients from turmeric source material include manganese (approximately 19.8 mg per 100g raw turmeric), iron (3.1 mg/100g), potassium (429 mg/100g), and vitamin C (approximately 25.9 mg/100g), though these are significantly concentrated or diluted depending on extraction ratio. Dietary fiber is largely removed during the extraction and concentration process. Protein content in the isolated extract is minimal (<1%). Bioavailability note: the cavitation process enhances curcumin's plasma absorption relative to unformulated curcumin, which typically demonstrates less than 1% oral bioavailability; however, specific pharmacokinetic parameters (Cmax, AUC) for CAVACURMIN specifically are derived from extraction methodology studies rather than human clinical trials.

Preparation & Dosage

No clinically studied dosage ranges are available for CAVACURMIN as no human trials have been conducted. The research provides no information on standardization, forms (extract, powder), or therapeutic doses. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

No synergistic ingredients identified in research

Safety & Interactions

General curcumin supplementation at doses up to 8,000 mg/day has demonstrated acceptable tolerability in short-term human studies, with the most commonly reported adverse effects being gastrointestinal in nature, including nausea, diarrhea, and bloating. Curcumin exhibits antiplatelet and anticoagulant properties, creating a clinically relevant interaction risk with warfarin, aspirin, clopidogrel, and other blood-thinning agents. It may also inhibit CYP3A4 and P-glycoprotein, potentially altering plasma concentrations of drugs metabolized via these pathways, including certain immunosuppressants and chemotherapy agents. Pregnant individuals should avoid high-dose curcumin supplementation due to its historical use as an emmenagogue and lack of established safety data in pregnancy.